Provision CARES Proton Therapy Nashville announces the opening of a new advanced proton therapy center and comprehensive cancer center in Franklin, TN. Provision CARES Proton Therapy Nashville is the newest development in the expansion of the Provision CARES Cancer Network, featuring proton therapy.
Provision Healthcare, an industry leading innovator in comprehensive, collaborative cancer solutions, is pleased to announce successfully treating the first patients on Provision’s newly developed ProNova SC360 proton therapy system at the Provision CARES Cancer Center in Knoxville, Tennessee. Read More
A cancer treatment center specializing in proton therapy, an increasingly popular treatment, is set to open in the summer of 2018.
Provision Healthcare, a clinical provider and developer of cancer treatments, will open a Provision CARES Cancer Center on Carothers Parkway, across from Williamson Medical Center, said Dr. Terry Douglass, Ph.D., the executive chair of Provision.
After nearly two years of construction, Provision CARES Proton Therapy Nashville is nearing completion of its $100 million cancer-treatment center — minus some areas of the roof.
That’s because crews still need to lower a 28-foot-diameter gantry — a structure about the size of an above-ground pool that rotates around a patient during therapy, allowing treatment from different angles —into place at the 45,000-square-foot facility.
More than 110,000 Tennesseans have Alzheimer’s disease. And, according to the Centers for Disease Control, the number of Alzheimer’s deaths in the Volunteer State has more than doubled since 1999. But modern medicine is helping doctors get in front of the mind-robbing disease. Doctors can now actually see signs of Alzheimer’s through special PET scans years before a patient develops severe symptoms. Click here for full story.
Provision Healthcare Advances Provision CARES Proton Therapy Center Development in Franklin with Arrival of Cyclotron
Franklin, Tennessee (July 20, 2017) – – Provision Healthcare is developing another advanced comprehensive Provision CARES Cancer Center in Franklin, TN which will include one of the most promising new cancer therapies now available – proton therapy. The Provision CARES Proton Therapy Center, a key feature of the cancer center, will utilize the latest advancement in proton therapy systems – the ProNova SC360. Read More
Provision Healthcare to Develop $100 Million Advanced Cancer Treatment Center in New Orleans
Louisiana Proton Therapy Center will be housed on University Medical Center campus in city’s biomedical corridor
NEW ORLEANS — Today, Gov. John Bel Edwards and Provision Healthcare CEO Terry Douglass announced the company and its partners will make a $100 million capital investment and build a 30,000-square-foot Louisiana Proton Therapy Center in the New Orleans biomedical corridor. Deploying advanced technology that produces far fewer side effects than conventional radiation treatments for cancer, Provision plans to develop the center on the University Medical Center campus on Canal Street. Read More
Knoxville, Tennessee, USA (December 8, 2016)—Provision Healthcare’s research, development and manufacturing subsidiary, ProNova Solutions, has received FDA 510(k) clearance for its SC360 proton therapy system only four years after commencing research and development. This is the first and only compact 360 degree pencil beam scanning proton therapy system capable of treating patients at all angles without moving the patient, enabling the most efficient clinical workflows, improved accuracy of treatment, and patient comfort. Read More
Provision Healthcare Announces National Survey ResultsMen treated for prostate cancer using proton therapy reported significantly better quality of life than other therapy options
Knoxville, TN (September 27, 2016) — A national survey released today reported that men treated for prostate cancer who received proton therapy reported significantly better quality of life during and after treatment than those treated with brachytherapy, surgery or traditional x-ray therapy. The survey carried out via phone and online, by Bryant Research profiled 755 men, ages 50-75, who were surveyed at least 12 months after treatment. Read More